Harpoon Therapeutics Inc   (HARP)
Other Ticker:  
Price: $22.9600 $0.02 0.087%
Day's High: $22.97 Week Perf: 0.09 %
Day's Low: $ 22.95 30 Day Perf: 2.91 %
Volume (M): 494 52 Wk High: $ 22.97
Volume (M$): $ 11,338 52 Wk Avg: $9.77
Open: $22.97 52 Wk Low: $3.11

 Market Capitalization (Millions $) 91
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) 33
 Net Income (TTM) (Millions $) 31
 Cash Flow (TTM) (Millions $) -53
 Capital Exp. (TTM) (Millions $) 0

Harpoon Therapeutics Inc
Harpoon Therapeutics Inc is a biotechnology company that develops immunotherapies to treat cancer. The company's approach focuses on using a proprietary technology called TriTAC (Tri-specific T cell Activating Construct) platform, which harnesses the power of the immune system to target and destroy tumor cells. Harpoon Therapeutics aims to create novel therapies that are more potent and targeted compared to traditional treatments, leading to improved outcomes for cancer patients. The company is based in South San Francisco, California and was founded in 2015.

   Company Address: 611 Gateway Boulevard South San Francisco 94080 CA
   Company Phone Number: 443-7400   Stock Exchange / Ticker: NASDAQ HARP
   HARP is expected to report next financial results on March 26, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Harpoon Therapeutics Inc

Harpoon Therapeutics Inc Reports Significant Improvement in Losses, Amidst Steep Decline in Revenue

Harpoon Therapeutics Inc (NASDAQ: HARP), a clinical-stage immunotherapy company, has recently announced its financial results for the most recent fiscal period. The company reported a loss of $-0.46 per share, which is a significant improvement compared to the loss of $-3.50 per share in the same period last year. Furthermore, the earnings per share (EPS) fell from $0.30 in the preceding quarter to the current level.
The revenue for Harpoon Therapeutics Inc fell sharply by -67.335% to $4.45 million in the mentioned period, compared to $13.62 million in the similar quarter a year prior. Sequentially, the revenue tumbled by -78.003% from $20.22 million. These revenue figures showcase the challenges the company is currently facing, highlighting the need for an effective strategy to boost its earnings.

Harpoon Therapeutics Inc

Astonishing Growth: Harpoon Therapeutics Inc. Outperforms Industry Peers, with Record Revenue Improvement of 143.538% in Q2 2023

/>Harpoon Therapeutics Inc., a leading player in the Medical Equipment & Supplies industry, recently released its financial results for the second quarter of 2023. The company has displayed remarkable growth, recording a notable revenue improvement of 143.538% year on year, reaching $20.22 million. In addition, Harpoon Therapeutics Inc. has turned a profit, with earnings per share standing at $0.03. These positive financial outcomes have positioned the company favorably among its industry peers.
Financial Results Overview:
Harpoon Therapeutics Inc.'s revenues exhibited impressive growth, outperforming the majority of its Medical Equipment & Supplies industry counterparts. Comparing the second quarter of 2023 with the same period last year, the company achieved a revenue improvement of 4.51%. This figure starkly contrasts the revenue growth observed by the two-thirds of other businesses in the Medical Equipment & Supplies industry.

Harpoon Therapeutics Inc

Harpoon Therapeutics Inc. Reports Impressive 45.327% Revenue Surge Amid Losses in Q1 2023

Harpoon Therapeutics Inc. is a biomedical company that lost money in the first quarter of 2023. The company reported a loss of $0.31 per share, despite a significant increase of 45.327% in revenue, which surged to $8.58 million from the similar financial reporting period a year ago. In contrast, the company realized no revenue in the preceding financial reporting period, and its share price was $1.29.
The company?s net deficit for the quarter ending March 31, 2023, was $-11.338 million, which is an improvement from the previous year's net loss of $-20.321 million for the same reporting period. It is a promising sign for the company that its loss has declined, signaling better control of expenses, and a more focused strategy in terms of finances and operations.


Harpoon Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com